Novel Index Combining Pan-Immune-Inflammatory Index and Hemoglobin Levels (PIV/Hb) Predicts Trismus Rates Efficiently after Chemoradiotherapy in Locally Advanced Nasopharyngeal Cancer.

IF 1.6 Q4 ONCOLOGY

International Journal of Surgical Oncology Pub Date : 2024-09-30 eCollection Date: 2024-01-01 DOI:10.1155/2024/2124006

Efsun Somay, Busra Yilmaz, Erkan Topkan, Beyza Sirin Ozdemir, Duriye Ozturk, Ali Ayberk Besen, Huseyin Mertsoylu, Ugur Selek

{"title":"Novel Index Combining Pan-Immune-Inflammatory Index and Hemoglobin Levels (PIV/Hb) Predicts Trismus Rates Efficiently after Chemoradiotherapy in Locally Advanced Nasopharyngeal Cancer.","authors":"Efsun Somay, Busra Yilmaz, Erkan Topkan, Beyza Sirin Ozdemir, Duriye Ozturk, Ali Ayberk Besen, Huseyin Mertsoylu, Ugur Selek","doi":"10.1155/2024/2124006","DOIUrl":null,"url":null,"abstract":"Purpose: To evaluate the predictive potency of a novel index combining the pan-immune-inflammatory index and hemoglobin levels (PIV/Hb) for the prevalence of radiation-induced trismus (RIT) in patients with locally advanced nasopharyngeal cancer (LA-NPC) receiving concurrent chemoradiotherapy (CCRT).Methods: Data from 228 LA-NPC patients were retrospectively examined. Maximum mouth openings (MMO) were measured to confirm the presence of RIT, defined as MMOs ≤35 mm. Complete blood test results from the first day of CCRT were used to calculate PIV/Hb levels. A potential relationship between pretreatment PIV/Hb and the RIT status was evaluated using receiver operating characteristic (ROC) curve analysis.Results: Post-CCRT RIT was diagnosed in 20.2% of the patients. The ROC curve analysis determined 68.4 g/dL as the ideal PIV/Hb cutoff that effectively divided patients into two distinct groups (area under the curve: 94.7%; specificity: 86.4%; sensitivity: 87.4%). RIT was significantly more prevalent in the PIV/Hb > 68 group than in the PIV/Hb < 68 group (58.8% vs. 3.8%; P < 0.001). Multivariate logistic regression analysis showed that a pre-CCRT PIV > 68 was independently associated with significantly higher rates of RIT.Conclusion: Higher pretreatment levels of the novel PIV/Hb index predict increased RIT rates following definitive CCRT for LA-NPCs.","PeriodicalId":45960,"journal":{"name":"International Journal of Surgical Oncology","volume":"2024 ","pages":"2124006"},"PeriodicalIF":1.6000,"publicationDate":"2024-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11458266/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Surgical Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1155/2024/2124006","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: To evaluate the predictive potency of a novel index combining the pan-immune-inflammatory index and hemoglobin levels (PIV/Hb) for the prevalence of radiation-induced trismus (RIT) in patients with locally advanced nasopharyngeal cancer (LA-NPC) receiving concurrent chemoradiotherapy (CCRT).

Methods: Data from 228 LA-NPC patients were retrospectively examined. Maximum mouth openings (MMO) were measured to confirm the presence of RIT, defined as MMOs ≤35 mm. Complete blood test results from the first day of CCRT were used to calculate PIV/Hb levels. A potential relationship between pretreatment PIV/Hb and the RIT status was evaluated using receiver operating characteristic (ROC) curve analysis.

Results: Post-CCRT RIT was diagnosed in 20.2% of the patients. The ROC curve analysis determined 68.4 g/dL as the ideal PIV/Hb cutoff that effectively divided patients into two distinct groups (area under the curve: 94.7%; specificity: 86.4%; sensitivity: 87.4%). RIT was significantly more prevalent in the PIV/Hb > 68 group than in the PIV/Hb < 68 group (58.8% vs. 3.8%; P < 0.001). Multivariate logistic regression analysis showed that a pre-CCRT PIV > 68 was independently associated with significantly higher rates of RIT.

Conclusion: Higher pretreatment levels of the novel PIV/Hb index predict increased RIT rates following definitive CCRT for LA-NPCs.

查看原文本刊更多论文

结合泛免疫炎症指数和血红蛋白水平（PIV/Hb）的新指数能有效预测局部晚期鼻咽癌化疗后的三联征发生率

目的：评估结合泛免疫炎症指数和血红蛋白水平（PIV/Hb）的新型指数对同时接受化学放疗（CCRT）的局部晚期鼻咽癌（LA-NPC）患者放射诱发三联征（RIT）发生率的预测效力：方法：对 228 名 LA-NPC 患者的数据进行了回顾性研究。测量最大张口度（MMO）以确认是否存在 RIT，MMO ≤35 mm 即为 RIT。CCRT 第一天的全血检验结果用于计算 PIV/Hb 水平。使用接收器操作特征（ROC）曲线分析评估了治疗前 PIV/Hb 与 RIT 状态之间的潜在关系：结果：20.2%的患者被诊断为CCRT后RIT。ROC 曲线分析确定 68.4 g/dL 为理想的 PIV/Hb 临界值，可有效地将患者分为两组（曲线下面积：94.7%；特异性：86.4%；灵敏度：87.4%）。PIV/Hb > 68 组的 RIT 发生率明显高于 PIV/Hb P < 0.001 组）。多变量逻辑回归分析显示，CCRT前PIV>68与RIT发生率明显较高独立相关：结论：新型 PIV/Hb 指数的预处理水平越高，预示着 LA-NPCs 确诊 CCRT 后的 RIT 率越高。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

International Journal of Surgical Oncology ONCOLOGY-

CiteScore

3.70

自引率

0.00%

发文量

审稿时长

20 weeks

期刊介绍： International Journal of Surgical Oncology is a peer-reviewed, Open Access journal that publishes original research articles, review articles, and clinical studies in all areas of surgical oncology.